Covidien plc (NYSE:COV) reported $0.96 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.95 by $0.01. The company had revenue of $2.60 billion for the quarter, compared to the consensus estimate of $2.61 billion. During the same quarter in the prior year, the company posted $1.12 earnings per share. The company’s quarterly revenue was up 2.7% on a year-over-year basis. Analysts expect that Covidien plc will post $3.99 EPS for the current fiscal year. Covidien plc (NYSE:COV) net profit margin is 15.50% and weekly performance is 18.62%. On last trading day company shares ended up $86.75. Analysts mean target price for the company is $79.25. Covidien plc (NYSE:COV) distance from 50-day simple moving average (SMA50) is 21.28%.
On 29 MAY Pernix Therapeutics Holdings Inc (NASDAQ:PTX) reported ($0.26) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.05) by $0.21. The company had revenue of $19.10 million for the quarter, compared to the consensus estimate of $23.65 million. Analysts expect that Pernix Therapeutics Holdings will post $-0.18 EPS for the current fiscal year. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) shares advanced 11.29% in last trading session and ended the day on $8.08. PTX Gross Margin is 50.20% and its return on assets is -11.20%. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) quarterly performance is 114.89%.
On 28 MAY TherapeuticsMD Inc (NYSEMKT: TXMD) and parent company of vitaMedMD, LLC (“vitaMedMD”) and BocaGreenMD, Inc. (“BocaGreenMD”), announced the availability of the newly reformulated vitaMedMD(R) branded prescription prenatal vitamin, vitaMedMD RediChew(TM) Rx, and the BocaGreenMD(R) generic prescription prenatal vitamin Prena1 Chew. vitaMedMD RediChew Rx and Prena1 Chew are small, vanilla flavored, chewable prenatal vitamin tablets that dissolve quickly and are taken once daily. TherapeuticsMD Inc (NYSEMKT: TXMD) shares moved up 9.50% in last trading session and was closed at $5.07, while trading in range of $4.65 – $5.15. TherapeuticsMD Inc (NYSEMKT: TXMD) year to date (YTD) performance is -2.69%.
On 22 MAY ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced results demonstrating the potent anti-tumor and anti-cancer stem cell (CTC) effects of Ad-RTS-IL-12 in a glioma (brain cancer) model, and in other preclinical and clinical settings. Ad-RTS-IL-12 is a novel DNA-based therapeutic candidate for the controlled expression of IL-12, an important protein for stimulating an anti-cancer T cell immune response. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) ended the last trading day at $4.27. Company weekly volatility is calculated as 5.67% and price to cash ratio as 7.12. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) showed a positive weekly performance of 4.66%.
On 5 JUNE Ampio Pharmaceuticals Inc (NYSEMKT: AMPE) announced the appointment of Gregory A. Gould as Chief Financial Officer, Treasurer, and Corporate Secretary. Mr. Gould, a veteran of the pharmaceutical and life sciences industry, is joining the company effective June 10th, 2014. Ampio Pharmaceuticals Inc (NYSEMKT: AMPE) weekly performance is 787%. On last trading day company shares ended up $7.82. Analysts mean target price for the company is $18.50. Ampio Pharmaceuticals Inc (NYSEMKT: AMPE) distance from 50-day simple moving average (SMA50) is 18.98%.